The English High Court has ordered the country’s National Health Service to issue guidance to medical professionals so that they prescribe Pfizer’s branded product Lyrica—not the generic version—for neuropathic pain.
Pharmaceutical companies Teva, Momenta, Mylan and Sandoz have asked the US Court of Appeals for the Federal Circuit for an expedited ruling on the validity of Teva’s patent covering its Copaxone drug.
A US court has ruled that an AstraZeneca patent covering asthma inhaler Pulmicort Respules is invalid, allowing generic drug makers to enter the market with their own versions.
Novartis has sued drug company BPI Labs for alleged patent infringement after it requested permission to market a generic version of Novartis’s bone cancer drug Zometa.
A medical aid non-profit organisation has opposed a European patent held by pharmaceutical company Gilead that covers its anti-hepatitis C drug Sovaldi.
Bayer’s animal health division has filed for a declaratory judgment that SHP Chemical has infringed three patents covering a range of products that control fleas affecting cats and dogs.
Another party has thrown its hat into the ring in the fight to stop the issue of an Indian patent covering Sovaldi, a hepatitis C drug.
The US Food and Drug Administration has approved an application by pharmaceutical company Teva to market a generic version of AstraZeneca’s heartburn drug Nexium.
The English High Court has said it will not send a patent infringement case filed by Pfizer-owned Warner-Lambert Company against Actavis to trial, finding there was no “serious issue”.
Teva has filed for a declaratory judgment that it did not infringe patents belonging to AstraZeneca and Amylin Pharmaceuticals that protect diabetes drug Byetta (exenatide).